EE51 A Cost-Consequence Analysis of Adopting Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma in Saudi Arabia: a Multi-Center Comparison
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.356
https://www.valueinhealthjournal.com/article/S1098-3015(23)00456-4/fulltext
Title :
EE51 A Cost-Consequence Analysis of Adopting Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma in Saudi Arabia: a Multi-Center Comparison
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00456-4&doi=10.1016/j.jval.2023.03.356
First page :
Section Title :
Open access? :
No
Section Order :
11737